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Abstract
Background: Brain-derived neurotrophic factor (BDNF) has been shown to control microglial responses in
neuropathic pain. Since adenosine A2A receptors (A2ARs) control neuroinflammation, as well as the production and
function of BDNF, we tested to see if A2AR controls the microglia-dependent secretion of BDNF and the
proliferation of microglial cells, a crucial event in neuroinflammation.
Methods: Murine N9 microglial cells were challenged with lipopolysaccharide (LPS, 100 ng/mL) in the absence or
in the presence of the A2AR antagonist, SCH58261 (50 nM), as well as other modulators of A2AR signaling. The BDNF
cellular content and secretion were quantified by Western blotting and ELISA, A2AR density was probed by Western
blotting and immunocytochemistry and cell proliferation was assessed by BrdU incorporation. Additionally, the A2AR
modulation of LPS-driven cell proliferation was also tested in primary cultures of mouse microglia.
Results: LPS induced time-dependent changes of the intra- and extracellular levels of BDNF and increased
microglial proliferation. The maximal LPS-induced BDNF release was time-coincident with an LPS-induced increase
of the A2AR density. Notably, removing endogenous extracellular adenosine or blocking A2AR prevented the
LPS-mediated increase of both BDNF secretion and proliferation, as well as exogenous BDNF-induced proliferation.
Conclusions: We conclude that A2AR activation plays a mandatory role controlling the release of BDNF from
activated microglia, as well as the autocrine/paracrine proliferative role of BDNF.
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Background
Neurodegenerative pathologies, such as Alzheimer’s or
Parkinson’s disease, progress with a sustained, chronic
neuroinflammatory process [1,2]. Microglial cells, which
display specialized immune functions in the central ner-
vous system, play a crucial role in neuroinflammation
[2,3], undergoing a process globally known as microglio-
sis. Microgliosis encompasses morphological changes,
cell proliferation and modifications in the synthesis and
secretion of both pro- and anti-inflammatory substances
[4], whose temporal balance determines the contention
or the perpetuation of neuroinflammation. Thus, neu-
roinflammation is a tightly regulated process involving
several modulators, including adenosine [5]. The relation
between adenosine and neuroinflammation is heralded
by the key role of adenosine A2A receptors (A2AR) in
peripheral inflammation [6], as well as by the loca-
lization of A2AR in microglial cells and the ability of
A2AR to control several microglial functions, namely
chemotaxis [7] and the production of inflammatory
mediators [8,9].
One of the most notable modulatory properties of ad-
enosine is the ability of A2AR activation to potentiate the
production, secretion and effects of different trophic fac-
tors [10]. This effect has been considered neuroprotec-
tive, in accordance with the ability of trophic factors to
prevent neuronal damage or to promote neuronal repair
[11-13]. However, it seems to contradict the well-
described neuroprotective role mediated by A2AR antag-
onism [14,15]. BDNF (brain-derived neurotrophic factor),
which is mostly recognized as a pro-survival factor, has
also been shown to support microglial activation in vivo
[16]. This could result in a potential amplification of
microgliosis and neuroinflammation, as occurs in neuro-
pathic pain [17,18], with BDNF release resulting either
through neuronal activity-dependent exocytosis or from
microglia using an exocytotic pathway or a constitutive
release pathway present in all cell types (reviewed in
[19]), both of which are prone to modulation [20,21].
Therefore, BDNF emerges as a potential candidate for
mediating the switch between acute neuroinflammation
(which is beneficial in resolving brain-noxious stimuli)
and chronic neuroinflammation, which is thought to be
a main player in the progression of neurodegenerative
diseases [2].
To date, it has not been explored whether A2AR con-
trols microglial levels of neurotrophic factors or its
involvement in autocrine/paracrine actions potentially
sustaining microgliosis over time. Thus, this study was
designed to test whether the A2AR blockade modulates
BDNF secretion and microglial proliferation induced by
the inflammatory trigger lipopolysaccharide (LPS), which
would indicate that A2AR acts as a key controller of
microglial function and neuroinflammation.
Methods
Cell line and primary microglial cultures
A murine microglial cell line, N9 (a kind gift from Professor
Claudia Verderio, CNR Institute of Neuroscience, Cellular
and Molecular Pharmacology, Milan, Italy), was grown in an
RPMI medium supplemented with 30 mM glucose (Sigma,
Sintra, Portugal), 100 U/mL penicillin and 100 μg/mL strep-
tomycin (GIBCO, Invitrogen, Porto, Portugal).
Primary microglial cultures were prepared as previously
described [22]. Briefly, primary cultures of glial cells were
obtained from a postnatal (P1-P5) C57BL6 mouse and
maintained for 15 days in the DMEM-F12 medium with
glutamax (Invitrogen) containing 10% fetal bovine serum
(Invitrogen), 0.25% gentamycin (Invitrogen) and 0.25 ng/mL
M-CSF (murine-colony stimulating factor, Peprotech, Rocky
Hill, New Jersey, USA). Microglia were then separated from
the mixed primary culture by shaking (200 rpm for 2
hours), and plated in the DMEM-F12 medium with gluta-
max containing 0.25% gentamycin (Invitrogen).
Cells were kept at 37°C under a humidified atmosphere
with 95% O2 and 5% CO2. Viable cells (identified by coun-
ting trypan-blue-excluding cellular elements) were plated
at a density of 5 × 105 cells per cm2 in 6 well trays for
Western blotting and enzyme-linked immunosorbent
assay (ELISA) or 1 × 105 cells per cm2 in 12 well trays for
proliferation and immunocytochemistry studies.
Microglial cell pharmacological treatment
In order to evaluate the ability of an inflammatory trigger
to control the cellular content of BDNF over time, N9 cells
were challenged with 100 ng/mL LPS (from Escherichia
coli, serotype 055:B5 from Sigma) for 3, 6 and 12 hours.
This concentration of LPS was chosen since it was previ-
ously shown to induce changes of A2AR density in micro-
glial cells [23], which we now aim to pharmacologically
manipulate to modulate BDNF secretion/function. Thus,
microglial cells were pre-incubated (20 minutes before
LPS) with a supra-maximal and selective concentration
(50 nM) of an A2AR antagonist, SCH58261 [24], which
was present until the end of the experiment (3, 6 or 12
hours). Given that we were able to identify the tipping time
point of the changes in BDNF levels and A2AR modulation
effects, subsequent experiments were carried out at this
time point (6 hours). In all these experiments, 20 to 30
minutes before adding LPS, N9 cells were incubated with
different modulators used in supra-maximal and selective
concentrations gauged from our previous experience in dif-
ferent preparations [25,26]: adenosine deaminase (ADA, 1
U/mL, which removes endogenous adenosine; Sigma), H89
(1 μM, a protein kinase A (PKA) inhibitor; Tocris, Madrid,
Spain), chelerythrine (6 μM, a protein kinase C (PKC) in-
hibitor; Calbiochem, Lisbon, Portugal), or anti-human
BDNF polyclonal antibody (10 μg/mL; Promega, Lisbon,
Portugal), a concentration chosen according to [27]. ADA
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and the anti-human BDNF polyclonal antibody were dir-
ectly diluted in the culture medium; H89 and chelerythrine
were made up to a 25 mM stock solution in water to dilute
in the culture medium.
In the experiments carried out in the absence of LPS, N9
cells were incubated with PKA upstream modulators used
in concentrations gauged from our previous experience
in different preparations (for example [25,26]), namely:
CGS21680 (30 nM; Sigma), an A2AR selective agonist; for-
skolin (1 μM; Ascent Scientific, Cambridge, UK), an activa-
tor of adenylate cyclase; 8-Br-AMP (5 μM; Tocris), a cyclic
AMP (cAMP) analog, or with exogenously added BDNF
(Sigma) used in a concentration (20 ng/mL) able to modu-
late A2AR-mediated neuronal functions [28]. BDNF was
directly diluted in the culture medium, whereas CGS21680
and forskolin were made up in dimethyl sulfoxide (100
mM) and 8-Br-AMP was made up in water (100 mM) to
dilute in the culture medium. We always tested the impact
of the vehicles of the drugs and modulators on each meas-
ure and found that all the used vehicles were devoid of
effects (data not shown).
Western blotting
Cell lysates were obtained in a lysis solution containing
150 mM NaCl, 50 mM Tris–HCl, 1 mM ethylenediamine
tetraacetic acid (EDTA), 1% NP-40 Igepal (Sigma, Sintra,
Portugal), 0.1% sodium dodecyl sulfate (SDS), 0.5% so-
dium deoxycolate, 1 mM (phenylmethylsulfonyl fluoride
(PMSF), 1 mM sodium ortovanadate, 1 mM NaF, 1 μg/mL
CLAP (protease inhibitor cocktail; Sigma). After cell scra-
ping for homogenization, the total amount of protein was
quantified using the bicinchoninic acid (BCA; Thermo
Scientific, Loures, Portugal) method. Samples were then
loaded onto gels with 7.5% (to detect A2AR, 50 kDa and
pro-BDNF, 37.5 kDa) or 15% (to detect mBDNF, 13 kDa)
of acrylamide plus bisacrylamide (BioRad, Amadora,
Portugal); proteins were separated by electrophoresis (100
to 120 V for 1 hour) using a bicine-buffered solution
(20 mM Tris, 192 mM bicine and 0.1% SDS, pH 8.3) and
then transferred (300 mV, 100 minutes, 4°C) to polyvinyli-
dene difluoride (PVDF) membranes (0.45 μm pore dia-
meter) (GE Healthcare, Little Chalfont, Buckinghamshire,
UK). Blots were then blocked for 1 hour at room tem-
perature (RT) with 5% low-fat milk in Tris-buffered saline
(20 mM Tris, 140 mM NaCl, pH 7.6, TBS) with 0.1%
Tween 20 (TBS-T) and incubated overnight at 4°C with
primary antibodies diluted in TBS-T with 0.5% low-fat
milk. The tested primary antibodies were mouse monoclo-
nal anti-BDNF (1:1000; Sigma) and mouse anti-A2AR
(1:1000; Millipore, Lisbon, Portugal). After rinsing three
times with 0.5% low-fat milk in TBS-T, membranes were
incubated for 1 hour at RT with alkaline phosphatase-
conjugated secondary antibodies (1:2000; Amersham,
Piscataway, New Jersey, USA). Protein immunoreactive
bands were visualized in a Versa Doc Imaging System
(Model 3000, BioRad Laboratories), after the incubation
of the membrane with enhanced chemofluorescence re-
agent (ECF; GE Healthcare).
Re-probing of the same membranes with a different
antibody was achieved by washing the ECF in 40% metha-
nol for 30 minutes and stripping the previous antibodies
in a solution of 0.2 M glycine with 0.1% SDS and 1% (v/v)
Tween 20, pH 2.2, for 1 hour. After washing (3 times with
TBS-T for 20 minutes), membranes were blocked and
incubated with primary and respective secondary anti-
bodies, namely for mouse anti-α-tubulin (1:20000; Sigma)
to confirm that similar amounts of sample were loaded to
the different lanes.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde (Sigma) and
permeabilized for 20 minutes in 0.25% Triton X-100
(Sigma) in a phosphate-buffered saline (PBS) solution
(137 mM NaCl, 2.7 mM KCl, 10 mM NaH2PO4, 1.8 mM
KH2PO4, pH 7.4). Unspecific binding was prevented by in-
cubating cells in PBS with 3% bovine serum albumin
(BSA) and 5% normal horse serum. Cells were incubated
overnight at 4°C in PBS with 3% BSA and 5% normal
horse serum and including the primary antibody (mouse
anti-A2A, 1:250; Millipore). Cells were then washed and
incubated for 1 hour at RT with an Alexa Fluor 488 don-
key anti-mouse (1:400; Molecular Probes, Lisbon, Portugal)
secondary antibody. Membrane ruffling, which is charac-
teristic of activated microglia, was probed using a marker
for filamentous actin, phalloidin, by incubating cells for 20
minutes at RT with PBS containing actin-stain 670 fluores-
cent phalloidin (1:75; Cytoskeleton, Denver, USA). For
nuclear labeling, N9 cells were stained with DAPI
(0.1 mg/mL; Invitrogen). The coverslips were mounted
in the Prolong Gold Antifade fluorescent medium
(Invitrogen). In order to check for non-specific labeling of
the secondary antibodies or cross-reactivity between sec-
ondary antibodies, staining was tested in the absence of
each primary antibody and in the absence of both primary
antibodies. Fluorescent images were acquired using a Zeiss
Imager Z2 fluorescence microscope equipped with an
AxioCam HRm and 63x Plan-ApoChromat oil objective
(1.4 numerical aperture), with Axiovision SE64 4.8.2 soft-
ware. Ten images were randomly taken from each cover-
slip (three per condition in each experiment).
BrdU incorporation assay
Microglial proliferation was evaluated by measuring the
incorporation of 5-bromo-2'-deoxyuridine (BrdU; Sigma),
a synthetic nucleoside that can be incorporated into newly
synthesized DNA, replacing thymidine during cell repli-
cation. Cells were incubated with BrdU (10 μM) for the
last 2 hours of pharmacological treatment, fixed in 4%
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paraformaldehyde, washed in TBS with 0.3% Triton X-100
and maintained in 1 M HCl at 37°C for 30 minutes. Non-
specific binding was prevented by incubation for 1 hour in
TBS with 3% BSA and 1% Triton X-100. Cells were incu-
bated overnight at 4°C with a primary rat antibody anti-
BrdU (1:100; Serotec, Oxford, UK) in a 0.1% Triton X-100
and 0.3% BSA solution, washed and incubated for 2 hours
at RT with an Alexa Fluor 594 donkey anti-rat secondary
antibody (1:200; Molecular Probes). For nuclear staining,
cells were incubated for 5 minutes at RT with Hoechst
33342 (10 μg/mL; Molecular Probes) in 0.3% BSA, and
mounted in Dakocytomation fluorescent medium (Dako-
cytomation Inc., California, USA). Fluorescent images
were acquired using an Axioskop 2 Plus fluorescence
microscope (Zeiss, PG-Hitec, Lisbon, Portugal). The num-
ber of proliferating cells (BrdU-positive) was counted and
expressed as a percentage of the total cells stained with
Hoechst 33342 [29].
BDNF enzyme-linked immunosorbent assay
The extracellular levels of BDNF were measured in the
supernatant of N9 cells using the BDNF Emax Immuno-
assay System (Promega, Madison, USA). Each well of a 96-
well polystyrene plate was incubated overnight at 4°C with
80 μL of anti-BDNF monoclonal antibody (1:1000) in coat-
ing carbonate buffer (50 mM, pH 9.7). Non-adsorbed anti-
body was discarded and rinsed off by washing once in a
TBS-T buffer (20 mM Tris–HCl, pH 7.6, 150 mM NaCl
and 0.05% (v/v) Tween 20). Unspecific binding was pre-
vented by blocking with 80 μL Promega 1x Block and
Sample Buffer (BB 1x) for 1 hour at RT. Plates were then
washed (as mentioned before) and 80 μL of each sample
or standard (7.8 pg/mL to 500 pg/mL) were loaded in trip-
licate to the plates (2 hours with 300 rpm shaking at RT).
After washing (5 times in TBS-T wash buffer), 80 μL of
anti-human BDNF polyclonal antibody (1:500 in BB 1x)
was added to each well and the plates were incubated at
RT (2 hours with 300 rpm shaking). After washing (5 times
in TBS-T wash buffer), the plates were incubated for 1
hour with shaking (300 rpm) with 80 μL anti-IgY horse-
radish peroxidase conjugate (1:200 in BB 1x). After the last
wash with the TBS-T buffer, 80 μl of TMB One solution
was used as developer and the reaction was stopped by
adding 80 μL of HCl 1 M. Absorbance was measured at
450 nm. BDNF levels are reported as pg/mL normalized
per total amount of protein.
Data analysis
Values are presented as mean ± standard error of the mean
(SEM) of n experiments. Either a Student’s t test for inde-
pendent means or a one-way analysis of variance (ANOVA)
followed by a Newman–Keuls post hoc test, was used to de-
fine statistical differences between absolute values, which
were considered significant at P < 0.05 unless otherwise
specified. Note that although the impact of several drugs
and modulators are presented as percentage values for the
sake of clarity, the statistical comparisons were always car-
ried out using the absolute values.
Results
LPS induces time-dependent changes in BDNF cellular
levels, an effect dependent upon adenosine A2A receptor
tonic activation
To explore the ability of A2AR to modulate BDNF levels
in microglial cells in response to an inflammatory stimu-
lus, we used a microglial cell line (N9), which has been
successfully used previously to dissect classical microglial
responses (secretion of inflammatory mediators, micro-
glial proliferation and phagocytosis) in inflammatory-like
conditions [30,31]. N9 cells were activated with LPS, a
component of the Gram-negative bacteria cell membrane,
which is a well-characterized inflammatory stimulus able
to induce microglial activation and the subsequent se-
cretion of trophic factors, including BDNF (for example
[9,12]).
We began testing the time course (3 up to 12 hours) of
the impact of LPS (100 ng/mL) on the intracellular levels
of BDNF. BDNF is synthesized as a precursor protein
(pro-BDNF), which is subsequently cleaved intra- and/or
extracellularly (by peptidases and convertases) to form
the mature protein (mBDNF) [19,32,33], which can be
detected by Western blot analysis (37.5 and 13 kDa, re-
spectively). In the present experimental conditions, LPS
(100 ng/mL) did not affect the cellular levels of pro-BDNF
at any given time point (Figure 1A,B, P > 0.05 compared
with non-treated cells). However, 6 hours of exposure to
LPS induced a decrease of the cellular levels of the mature
protein (74.9 ± 4.3%, n = 7, P < 0.001 compared with non-
treated cells), which returned to values similar to those
observed in non-treated cells 6 hours later, that is, at 12
hours of exposure to LPS (Figure 1A,B).
We have previously reported that LPS is able to induce
microgliosis and the production of pro-inflammatory
mediators under A2AR control [9]. In parallel, it is known
that A2AR modulates BDNF levels both in neurons [34]
and in native tissue [35]. Since this effect has not yet been
reported in microglia, we tested the ability of a supra-
maximal and selective concentration (50 nM) of an A2AR
antagonist, SCH58261 [24], to control BDNF levels in the
absence and in the presence of LPS. As shown in Figure 2,
the A2AR antagonist prevented the LPS-induced decrease
of mBDNF at 6 hours (129.5 ± 23.04%, n = 5, P < 0.01
compared with LPS-treated cells, Figures 2B,D), whereas
SCH58261 was devoid of effects on BDNF levels either
when LPS has no effects (that is, at 3 or 12 hours;
Figure 2A,C) or in the absence of LPS (P > 0.05 compared
with non-treated cells or LPS-treated cells for 3 and 12
hours).
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LPS-induced decrease of BDNF cellular levels is related to
an increase of BDNF secretion, an effect dependent upon
a tonic activation of A2AR
The LPS-induced decrease of mBDNF at 6 hours of expos-
ure may be explained by changes in BDNF expression
and/or secretion. The fact that LPS did not influence the
levels of pro-BDNF (see Figures 1 and 2) suggests that
changes in secretion are more likely to be involved. Thus,
we tested the influence of LPS upon BDNF secretion by
measuring free mature BDNF levels in the culture
medium, as assessed by ELISA. Endogenous levels of
BDNF in non-treated cells (196.2 ± 37.6 pg/mL, n = 9,
Figure 3A) were increased by 147.3 ± 12% (n = 9, P < 0.01)
in the presence of LPS (100 ng/mL for 6 hours), reaching
extracellular values of 272.1 ± 51.3 pg/mL (Figure 3A,B).
The A2AR antagonist, SCH58261 (50 nM), notably pre-
vented this LPS-induced BDNF secretion (93.6 ± 8.7%,
n = 9, P < 0.01 compared with LPS-treated cells,
Figure 3B). These results indicate that A2AR activation by
endogenous adenosine is required to allow the LPS-
induced secretion of BDNF. Accordingly, the presence of
ADA (1 U/mL), which removes endogenous adenosine
thus impairing A2AR activation, also prevented the effect
of LPS upon BDNF release (104.7 ± 4.2%, n = 5, P < 0.01
compared with LPS-treated cells, Figure 3B).
A2AR control the LPS-induced secretion of BDNF through
the cAMP-PKA pathway
The key role of A2AR in mediating the LPS-induced secre-
tion of BDNF suggests that the direct activation of A2AR
should be able to trigger the release of BDNF from mi-
croglial N9 cells. Indeed, the selective A2AR agonist,
CGS21680 (30 nM), enhanced per se (that is, in the ab-
sence of LPS) the secretion of BDNF (146.2 ± 14.3%, n = 4,
P < 0.05 compared with non-treated cells) to an extent
similar to the effect of LPS (P > 0.05 compared with LPS-
treated cells), an effect prevented by the A2AR antagonist
SCH58261 (50 nM) (96.3 ± 10%, n = 4, P < 0.01 compared
with CGS21680-treated cells) (Figure 4A).
A2AR are G protein-coupled receptors and most of their
effects involve AC activation and the subsequent raise in
cAMP levels, which activate PKA (for a review, see, for ex-
ample, [36]). Accordingly, adenosine modulates peripheral
immune responses through the activation of A2AR and the
recruitment of the cAMP-PKA pathway [6]. It has pre-
viously been reported that PKA notably plays a crucial
role in the control of the depolarization-evoked release of
BDNF from neurons [20]. Thus, we tested to see if the
AC-cAMP-PKA pathway would control BDNF secretion
from microglial cells. As shown in Figure 4B, the activa-
tion of AC with forskolin (1 μM) or the cAMP analog
8-bromo-cAMP (5 μM), mimicked the effect of LPS, trig-
gering BDNF secretion (147.4 ± 9.1%, n = 5, P < 0.001
compared with non-treated cells and 120.9 ± 3.4%, n = 5,
P < 0.01 compared with non-treated cells) to an extent
similar to that caused by LPS (both have P > 0.05 com-
pared with LPS-treated cells). Compatible with this sce-
nario, we report that the PKA inhibitor H89 (1 μM)
prevented the effect of LPS upon BDNF secretion (95.8 ±
7.7%, n = 6, P < 0.01 compared with LPS-treated cells,
Figure 4C), further suggesting that the tonic activation by
endogenous adenosine of A2AR operating through the
cAMP-PKA pathway underlies the ability of LPS to trigger
BDNF secretion.
Notably, we observed that H89 failed to modify the basal
outflow of BDNF from microglial N9 cells (Figure 4C), in-
dicating that the AC-cAMP-PKA pathway can be recruited
by A2AR to bolster the release of BDNF upon LPS-induced
microgliosis, but does not mediate the constitutive release
of BDNF. In contrast, the PKC inhibitor, chelerythrine
(6 μM), enhanced the constitutive outflow of BDNF (160.3
± 12.3%, n = 4, P < 0.05 compared with non-treated cells;
Figure 4C), but failed to affect the LPS-induced secretion
Figure 1 Effect of LPS on the intracellular levels of pro- and
mature BDNF in murine N9 microglial cells. (A) N9 cells were
exposed to LPS (100 ng/mL) for 3, 6 and 12 hours, then lysed and
homogenized for Western blot analysis of pro- (open bars) and mature
BDNF (filled bars) immunoreactivities (37.5 and 13 kDa, respectively).
Results are expressed as mean ± SEM of n (as indicated in each bar)
independent experiments (*** P < 0.001, compared with non-treated
cells, using the Newman–Keuls multiple comparison test) and 100%
represents the pro- and mBDNF in cells that were not exposed to LPS.
(B) Representative blot of the LPS (100 ng/mL for 6 hours)-mediated
decrease of intracellular mature BDNF and its inability to interfere with
the intracellular levels of pro-BDNF; the blots compare BDNF
immunoreactivity from cells exposed (+) or not (−) to LPS. BDNF, brain-
derived neurotrophic factor; LPS, lipopolysaccharide; mBDNF, mature
protein BDNF; SEM, standard error of the mean.
Gomes et al. Journal of Neuroinflammation 2013, 10:16 Page 5 of 13
http://www.jneuroinflammation.com/content/10/1/16
of BDNF (146.4 ± 15.0%, n = 4, P > 0.05 compared with
LPS-treated cells; Figure 4C). This indicates that the
transducing pathways involved in the constitutive and
LPS-induced release of BDNF are different and that the
LPS-induced enhancement of BDNF secretion selectively
recruits the A2AR operating the cAMP-PKA pathway.
In accordance with our working hypothesis that the
LPS-induced release of BDNF requires the recruitment of
A2AR and the activation of the AC-cAMP pathway, we
expected to record an ability for CGS21680 (an activator
of A2AR), forskolin (an activator of AC) or 8-Br-cAMP to
occlude the ability of LPS to enhance BDNF release. Sur-
prisingly, we observed that the activation of the A2AR-AC-
cAMP system before the LPS challenge actually changed
the set-up of the N9 cells to such an extent that the simul-
taneous presence of LPS and any of the activators of the
A2AR-AC-cAMP axis (30 nM CGS21680, 1 μM forskolin
or 5 μM 8-Br-cAMP) now failed to modify (P > 0.05) the
release of BDNF compared to the control (Figures 4A,B).
This prompts the hypothesis that the LPS signaling
pathway or the ability to release BDNF might be affected
by this pre-exposure to these activators of the A2AR-AC-
cAMP axis, a question that warrants further detailed
mechanistic investigation.
This different role for A2AR in the control of LPS-induced
enhancement of BDNF secretion (LPS requires the subse-
quent activation of A2AR, whereas the pre-activation of
A2AR inhibited the LPS-induced release of BDNF) led us to
test the hypothesis that LPS might up-regulate A2AR to bol-
ster BDNF secretion from N9 microglial cells. As shown in
Figure 5, both Western blot (Figure 5A,B) and immuno-
cytochemical (Figure 5C) analysis of N9 cells revealed an
enhancement of A2AR immunoreactivity at the same time
point where LPS-induced enhancement of BDNF secretion
was observed (that is, at 6 hours). The temporal correlation
between the enhancement of A2AR density and the PKA-
dependent increase of BDNF secretion suggests that LPS-
induced PKC-PKA shifting in the regulation of BDNF
secretion may be triggered by the increased A2AR signaling
subsequent to an increase in receptor density and activation.
Figure 2 Effect of LPS on the intracellular levels of pro- and mature BDNF in the presence of a selective A2AR antagonist in murine N9
microglial cells. The A2AR antagonist SCH58261 (50 nM) prevented the LPS (100 ng/mL)-induced modification of mature BDNF levels selectively
at 6 hours (B). In contrast, the A2AR blockade failed to affect the levels of pro- and mature BDNF at 3 hours (A) or 12 hours (C) of LPS exposure.
Note that A2AR only affected BDNF levels when they were challenged with LPS. Results are expressed as mean ± SEM of n (as indicated in each
bar) independent experiments (*** P < 0.001, compared with non-treated cells; •• P < 0.01, compared with LPS-treated cells, using the Newman–
Keuls multiple comparison test) and 100% represents the pro- and mBDNF in cells that were not exposed to LPS. (D) Representative blot of the
modulation by SCH58261 of intracellular mature BDNF in cells challenged for 6 hours with LPS. We verified (not shown) that none of the vehicles
of the tested drugs (water or dimethyl sulfoxide) modified BDNF levels. A2AR, A2A receptor; BDNF, brain-derived neurotrophic factor; LPS,
lipopolysaccharide; mBDNF, mature protein BDNF; SEM, standard error of the mean.
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Figure 3 Endogenous extracellular adenosine, through activation of A2AR, mediates the LPS-induced enhancement of BDNF secretion
from microglial N9 cells. Cells were incubated with LPS (100 ng/mL for 6 hours) in the absence or in the presence of the A2AR antagonist,
SCH58261 (50 nM) or in the absence or presence of adenosine deaminase (ADA, 1 U/mL), which converts adenosine into its inactive metabolite,
inosine. The incubation medium was collected to quantify the extracellular free mature BDNF by ELISA. (A) Comparison between absolute values
of BDNF (pg/mL) in the absence and in the presence of LPS. (B) LPS increased the extracellular levels of BDNF, an effect prevented by A2AR
antagonism and by adenosine removal from the medium with ADA (percentage of effect; 100% represents BDNF levels in cells that were not
exposed to LPS). Results are expressed as mean ± SEM of n (as indicated in each bar) independent experiments (** P < 0.01, compared with non-
treated cells; •• P < 0.01, compared with LPS-treated cells, using the Newman–Keuls multiple comparison test). We verified (not shown) that none
of the vehicles of the tested drugs (water or dimethyl sulfoxide) modified BDNF levels. A2AR, A2A receptor; ADA, adenosine deaminase; BDNF,
brain-derived neurotrophic factor; LPS, lipopolysaccharide; SEM, standard error of the mean.
Figure 4 The LPS-induced enhancement of BDNF secretion mediated by A2AR involves the recruitment of the AC-cAMP-PKA
transducing pathway, whereas PKC controls the constitutive release of BDNF from N9 microglial cells. In all experiments, the medium
was collected after 6 hours for quantitative analysis of extracellular BDNF (ELISA). (A) Cells were incubated with the A2AR agonist CGS21680 (30
nM) in the absence or in the presence of the A2AR antagonist SCH58261 (50 nM) or LPS (100 ng/mL). (B) Cells were incubated with the adenylyl
cyclase (AC) activator, forskolin (1 μM) or with the cAMP analog, 8-Br-cAMP (5 μM) in the absence and in the presence of LPS (100 ng/mL). (C)
Cells were incubated with the PKA inhibitor, H89 (1 μM) or with the PKC inhibitor, chelerythrine (6 μM) in the absence and in the presence of LPS
(100 ng/mL). Results are expressed as mean ± SEM of n (as indicated in each bar) independent experiments (*** P < 0.001, ** P < 0.01, * P < 0.05,
compared with non-treated cells; •• P < 0.01, compared with LPS-treated cells, using the Newman–Keuls multiple comparison test) and 100%
represents the pro- and mBDNF in cells that were not exposed to LPS. We verified (not shown) that none of the vehicles of the tested drugs
(water or dimethyl sulfoxide) modified BDNF levels. A2AR, A2A receptor; ADA, adenosine deaminase; BDNF, brain-derived neurotrophic factor;
cAMP, cyclic AMP; LPS, lipopolysaccharide; PKA, protein kinase A; PKC, protein kinase C; SEM, standard error of the mean.
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LPS promotes microglial proliferation, an effect
dependent upon BDNF and A2AR tonic activation
Given that both BDNF and A2AR activation promote
neuroinflammation and A2AR was previously proposed
to be required for microglial proliferation [37], we next
aimed to extend understanding of the tight interplay be-
tween BDNF and A2AR in the context of the control of
microglial proliferation, a key process for sustaining neu-
roinflammation. We posited that one of the functions of
BDNF released under LPS stimulation of microglial cells
might be to promote their proliferation in order to ‘feed’
microgliosis, an effect which might also be controlled by
A2AR. To begin probing this hypothesis, we first tested
the impact of an antibody that specifically recognizes
and sequesters BDNF on the LPS-induced proliferation
of N9 microglial cells. As anticipated, LPS (100 ng/mL
for 6 hours) induced a clear proliferation of N9 micro-
glial cells (170.5 ± 9.2%, n = 6, P < 0.01 compared with
non-treated cells). Notably, this effect was prevented
when the cells were simultaneously incubated with the
antibody anti-BDNF (79.4 ± 3.5%, n = 3, P < 0.001 com-
pared with LPS-treated cells; Figure 6A,B). Furthermore,
in line with the ability of A2AR to control LPS-induced
BDNF secretion, we observed that the A2AR antagonist,
SCH58261 (50 nM), prevented the LPS-induced increase
of N9 microglial cell proliferation (90.4 ± 8.1%, n = 3,
P < 0.01 compared with LPS-treated cells, Figure 6A,C).
In order to disentangle whether the A2AR blockade was
only preventing BDNF secretion or also the impact of
BDNF on microglial proliferation, we then evaluated the
Figure 5 Effect of LPS on the density of A2AR in N9 microglial cells. (A) Representative blot of the LPS (100 ng/mL for 6 hours)-mediated
increase of A2AR density; the blot compares A2AR immunoreactivity from cells exposed (+) or not (−) to LPS in four independent experiments. (B) Cells
were exposed to LPS (100 ng/mL for 6 hours) and then lysed and homogenized for Western blot analysis. Quantitative analysis of A2AR
immunoreactivity in the presence of LPS was compared with non-treated cells (taken as 100%). Results are expressed as mean ± SEM of n
(as indicated in each bar) independent experiments (* P < 0.05, compared with non-treated cells, using Student’s t test). (C) Immunocytochemistry
confirmed the LPS-induced increase in A2AR immunoreactivity (representative images of independent experiments). Double-labeling for A2AR (green)
and for the structural protein, phalloidin (far red), was performed in all experiments; phalloidin-labeling is not shown to allow a clear visualization of
A2AR immunoreactivity (the nuclei were labeled with DAPI, in blue). (D) Magnification of cellular elements 1 (microglia in basal conditions) and 2
(activated cell) in (C), showing in detail the increase in A2AR density in activated cells (phalloidin-labeling is shown to allow the visualization of LPS-
induced morphological changes of microglial cells). A2AR, A2A receptor; LPS, lipopolysaccharide; SEM, standard error of the mean.
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ability of exogenously added BDNF to directly trigger the
proliferation of N9 microglial cells, as well as the ability
of SCH58261 to modulate this eventual effect. BDNF
(20 ng/mL) increased the proliferation of N9 microglial cells
(242 ± 48%, n = 3, P < 0.01 compared with non-treated
cells), an effect prevented by the antibody anti-BDNF
(104.3 ± 4.1%, n = 3, P < 0.05 compared with BDNF-treated
cells, data not shown) and by the A2AR blockade (147.7 ±
47%, n = 3, P < 0.05 compared with BDNF-treated cells) or
removal of endogenous adenosine with 1 U/mL of ADA
(111.2 ± 29%, n = 3, P < 0.01 compared with BDNF-treated
cells, Figure 6D,E).
Finally, we attempted to extend the A2AR-mediated con-
trol of BDNF-induced proliferation from the context of
N9 microglial cells to that of mouse microglia. These
mouse primary cultures of microglia (n = 2 in triplicate)
were exposed to LPS (100 ng/mL) or to BDNF (20 ng/mL)
for 6 hours: both LPS (251.1 ± 12.8%, P < 0.01 compared
with non-treated cells, Figure 7A,B) and BDNF (201.1 ±
2.6%,P < 0.05 compared with non-treated cells, Figure 7A,
B) increased primary microglial proliferation, an effect pre-
vented by the A2AR blockade with SCH58261 (50 nM).
Discussion
The present study suggest two major conclusions: 1) the
activation of microglial cells with LPS triggers a release of
BDNF, which plays a key autocrine or paracrine role by
stimulating microglial proliferation; 2) both the LPS-
induced release of BDNF as well as the resulting prolifera-
tion of microglia is prevented by the blockade of adenosine
A2AR.
Figure 6 LPS triggers microglial N9 proliferation in a manner dependent on extracellular BDNF and A2AR activation. Cells were exposed
to LPS (100 ng/mL) for 6 hours in the presence of BrdU for the last 2 hours. Proliferation was quantified as the number of BrdU-labeled nuclei (red)
and expressed as a percentage of the total number of DAPI-labeled nuclei (blue). (A) Representative images illustrating the ability of LPS to enhance
N9 microglial cell proliferation, an effect prevented both by an anti-BDNF antibody (10 μg/mL) and by the selective A2AR antagonist, SCH58261
(50 nM). Average quantitative analysis shows that anti-BDNF antibody (B) or SCH58261 (C) prevents LPS-induced proliferation. (D) Representative
images illustrating the ability of added BDNF (20 ng/mL) to enhance N9 microglial cells proliferation, an effect prevented both by the selective A2AR
antagonist, SCH58261 (50 nM) and by adenosine deaminase (ADA, 1 U/mL). Average quantitative analysis shows the ability of SCH58261 (50 nM) and
ADA (1 U/mL) to prevent BDNF effects (E). Results are expressed as mean ± SEM of n (as indicated in each bar) independent experiments (** P < 0.01,
compared with non-treated cells; ••• P < 0.001, •• P < 0.01, compared with LPS-treated cells; •• P < 0.01, • P < 0.05 compared with BDNF-treated cells
using the Newman–Keuls multiple comparison test) and 100% represents proliferation of cells that were not exposed to LPS. A2AR, A2A receptor; ADA,
adenosine deaminase; BDNF, brain-derived neurotrophic factor; LPS, lipopolysaccharide; SEM, standard error of the mean.
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In response to noxious stimuli, microglia become acti-
vated by changing their morphology, proliferating and re-
leasing molecules, some considered to be neurotoxic and
others neuroprotective [1]. Irrespective of the nature of
the released substances, microglial responses in the cen-
tral nervous system must be tightly regulated since the
sustained activation of microglia results in a chronic neu-
roinflammatory process, which is involved in neurodegen-
eration. Neurotrophic factors, namely BDNF, which are
produced and secreted by microglial cells [21,38,39], have
the ability to protect neurons and to promote neuronal re-
pair in pathologic-like conditions [11-13]. Although the
physiological role of BDNF in neuronal survival/repair
has been extensively investigated, the autocrine/paracrine
function of BDNF secreted by microglial cells has not
been addressed and may actually play a deleterious role.
Thus, BDNF can actually behave as a switch by promoting
an autocrine action in microglial cells, which may lead to
their sustained activation, as occurs in spinal cord cells
during neuropathic pain [17]: in this disease, BDNF exa-
cerbates pain hypersensitivity, and strategies to prevent
BDNF-mediated microgliosis are considered to have the-
rapeutic potential [18,40]. The present study with cultured
N9 microglial cells provides the first direct demonstration
for a key autocrine/paracrine role of BDNF in the LPS-
induced proliferation of microglial cells: thus, LPS triggers
the secretion of BDNF, which we showed to be directly re-
sponsible for the proliferation of microglial cells.
The second major novel conclusion of this study was the
ability of the A2AR blockade to prevent LPS-induced
microglial proliferation, as a result of the dual ability of
A2AR to control the LPS-induced secretion of BDNF and
the ability of this BDNF to trigger microglial proliferation.
These observations are in agreement with the ability of the
A2AR blockade to control in vitro microglial proliferation
[37]; they are also heralded by the numerous reports show-
ing that A2AR controls microglial activation, namely res-
ponses triggered by LPS [8,41], as well as microgliosis in
animal models of inflammatory disease [9,42-44]. In par-
ticular, the present results that both the induced secretion
of BDNF as well as its impact on microglial cells are
dependent on A2AR activation, provide the first direct de-
monstration for a tight interplay between A2AR and BDNF
signaling in glial cells, extending the previously reported
tight interaction between A2AR and different neurotrophic
factors in the control of neuronal responses [45-47]. In
contrast to neuronal interactions between BNDF and
A2AR, which were revealed in physiological-like processes,
the interaction between A2AR and BDNF in microglial cells
seems to occur selectively under pathologic-like conditions
typified by microglial activation. Thus, the effect of A2AR is
not observed in the absence of LPS and the LPS-induced
Figure 7 LPS and BDNF trigger primary microglial proliferation in a manner dependent on A2AR activation. Cells were exposed to LPS
(100 ng/mL) for 6 hours in the presence of BrdU for the last 2 hours. Proliferation was quantified as the number of BrdU-labeled nuclei (red) and
expressed as a percentage of the total number of DAPI-labeled nuclei (blue). (A) Representative images illustrating the ability of LPS and BDNF to
enhance primary microglial proliferation, an effect prevented by the selective A2AR antagonist, SCH58261 (50 nM) (B). Results are expressed as
mean ± SEM of two independent experiments (** P < 0.01, *** P < 0.001, compared with non-treated cells; •• P < 0.01, • P < 0.05, compared with
LPS-treated cells) and 100% represents proliferation of cells that were not exposed to LPS. A2AR, A2A receptor; ADA, adenosine deaminase; BDNF,
brain-derived neurotrophic factor; BrdU, 5-bromo-2'-deoxyuridine; LPS, lipopolysaccharide; SEM, standard error of the mean.
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release of BDNF is notably time-dependent and time-
coincident with the increase in A2AR density, strongly sug-
gesting a role for the up-regulation of A2AR in activated
microglia as a trigger for this interaction, in agreement with
the previously reported selective role of A2AR in the patho-
physiology of neuroinflammation [9,44,48-50]. It is import-
ant to recognize that the present results are in general
agreement with the observation that it is the blockade of
A2AR that prevents neuroinflammation, which is in clear
contrast with the anti-inflammatory effect resulting from
A2AR activation in the control of peripheral inflammation
[6] or central pathological conditions, in particular when
peripheral cells invade the central nervous system, as
occurs through disruption of the blood–brain barrier,
where immunosuppressive actions may be mediated by
A2AR activation rather than blockade [51,52]. The mechan-
ism underlying this contradiction remains to be elucidated.
The impact of A2AR in controlling inflammation may de-
pend on the type of immune cell involved, as well as the
particular conditions found in the brain parenchyma [8], as
previously discussed [53]. Considering that the A2AR gene
has independent promoters [54], region-specific transcrip-
tional control of A2AR may explain differences between
central and peripheral immune responses.
The final interesting conclusion from this study is the
observation that LPS redirects the intracellular pathway
involved in the regulation of BDNF secretion from PKC to
PKA. Considering the parallel increase in A2AR density,
this shift is likely due to an increase in A2AR signaling. In-
deed, the basal outflow of BDNF seems to be affected by a
blockade of PKC but not of PKA; in contrast, the LPS-
induced outflow of BDNF, shown to be mediated by the
endogenous activation of the up-regulated A2AR, was pre-
vented by PKA rather than PKC inhibition, suggesting a
reorganization of the control of BDNF outflow upon
microglial activation by LPS (Figure 8).
Conclusion
In inflammatory conditions microglial cells are activated
and proliferate, which is a beneficial response if self-
limited, but can become detrimental if sustained. The
present study shows that BDNF secretion upon microglial
activation plays an autocrine/paracrine role bolstering
microglial proliferation, which may drive sustained micro-
gliosis. Furthermore, we provide the first demonstration
that adenosine A2AR play a key dual role in the control of
BDNF secretion upon microglial activation, as well as on
BDNF-induced proliferation of microglial cells. This pro-
vides the first direct demonstration for the interplay be-
tween A2AR and BDNF in glial cells and provides a novel
mechanistic insight into the therapeutic potential of A2AR
antagonists to control neurodegenerative conditions
where chronic neuroinflammation is present.
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